Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 143

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 143
---
. Reveles is board certified by the American Society of Clinical Pathology as a clinical specialist in cytogenetics who has successfully launched multiple diagnostics and commercial laboratories. We have attracted experienced salespeople with a proven record in the pulmonary field. In November 2023, we hired a National Sales Director who has more than 15 years of experience in medical sales and marketing, most recently as Executive Account Manager for the respiratory portfolio of Olympus America’s therapeutic solutions division. Our innovative and collaborative culture is in part responsible for our ability to attract and retain highly skilled professionals seeking professional advancement. Outside partnerships and collaborations that advance business and scientific research are encouraged, allowing us to multiply workforce efforts without expending significant capital.

| 77 |

Implications of Being an Emerging Growth Company and a Smaller Reporting Company

We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For as long as we remain an emerging growth company, we may take advantage of specified reduced reporting requirements and other burdens that are otherwise applicable generally to other public companies. These provisions include, but are not limited to:

| ● | reduced                                                                                                                                
 obligations with respect to financial data, including presenting only two years of audited financial statements and selected financial 
 data, and only two years of related Management’s Discussion and Analysis of Financial Condition and Results of Operations disclosure   
 in our initial registration statement;                                                                                                 |
| ● | an                                                                                                                                     
 exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to      
 the Sarbanes-Oxley Act of 2002, as amended (“SOX”);                                                                                    |
| ● | reduced                                                                                                                                
 disclosure about executive compensation arrangements in our periodic reports, registration statements, and proxy statements; and       |
| ● | exemptions                                                                                                                             
 from the requirements to seek non-binding advisory votes on executive compensation or stockholder approval of any golden parachute     
 arrangements.                                                                                                                          |

We may take advantage of some or all of these provisions until we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (1) the last day of the fiscal year following the fifth anniversary of the completion of our initial public offering, (2) the last day of the first fiscal year in which our annual gross revenues exceed $1.235 billion, (3) the date on which we have, during the immediately preceding three-year period, issued more than $1.0 billion in non-convertible debt securities and